Development and validation of a liquid chromatographic method for Casiopeina IIgly® in rat plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 791, Issue 1-2, 2003, Pages 111-116

  Reyes, Leobardo ^a   Fuentes Noriega, Inés ^a   Ruiz Ramìrez, Lena ^a   Macías, Lucía ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Casiopeina IIgly; Validation

Indexed keywords

CLINICAL LABORATORIES; METHANOL; PLASMAS; WATER;

SOLID-PHASE EXTRACTION;

LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENT; AQUA[(4,7 DIMETHYL 1,10 PHENANTHROLINE GLYCINE COPPER)NITRATE]; CASIOPEINA IIGLY; METHANOL; UNCLASSIFIED DRUG; WATER;

ACCURACY; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DEVICE; DRUG BLOOD LEVEL; DRUG DETERMINATION; EFFLUENT; EVALUATION; LINEAR SYSTEM; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID PHASE EXTRACTION; VALIDATION PROCESS;

EID: 0038021437     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-0232(03)00226-5     Document Type: Article

References (18)

1. L. Ruiz-Azuara. Process to obtain new mixed copper aminoacidate complexes from phenylatephenanthroline to be used as anticancerigenic agent. U.S. Patent Ap21 (1992) Number 5, 107, 005. U.S. Patent Re35, 458, Feb. 18 (1997).
2. L. Ruiz-Azuara. Process to obtain new mixed copper aminoacidate from methyl phenanthroline complexes to be used as anticancerigenic agents. U.S. Patent Pat. No. A5576326. Nov. 19 (1996).
3. ®Mark Tittle: Casiopeina. Reg 407543 SECOFI (1992).
4. Gracia-Mora I., Ruiz-Ramírez L., Gómez-Ruiz C., Tinoco-Méndez M., et al. Metal Based Drugs. 8:(1):2001;19.
5. Gasque L., Ruiz-Ramírez L., Moreno-Esparza R. J. Inorg. Biochem. 48:(2):1992;121.
6. Ruiz-Ramírez L., Gasque L., Martínez A., Moreno-Esparza R., Solans X. Acta Crystallogr. C49:1993;227.
7. Álvarez A., Briansó J.L., Piniella J.F., Moreno-Esparza R., Ruiz-Ramírez L., Ferrer-Sueta G. Acta Crystallogr. C51:1995;852.
8. Moreno-Esparza R., Molins E., Briansó J.L., Ruiz-Ramírez L., Redón L. Acta Crystallogr. C51:1995;1505.
9. Ferrer G., Ruiz-Ramirez L., Radi R. J. Chem. Res. Toxicol. 10:(12):1997;1338.
10. Fuentes-Noriega I., Ruiz-Ramírez L., Tovar-Tovar A., Rico-Morales H., Gracia-Mora I. J. Chromatogr. B. 772:2002;115.
11. de Vizcaya-Ruiz A., Rivero-Muller A., Ruiz-Ramírez L., Kass G.E.N., Kelland L.R., Orr R.M., Dobrota M. Toxicol. Vitro. 14:2000;1.
12. United States Pharmacopeia XXIII, The United States Pharmacopeial Convention, Rockville, MD:1994;1929.
13. Bresolle F., Bromet-Petit M., Audran M. J. Chromatogr. B. 686:1996;3.
14. Solans X., Ruiz-Ramírez L., Gasque L., Martínez A., Moreno-Esparza R. Acta Crystallogr. C49:1993;890.
15. Lang J.R., Bolton S. J. Pharm. Biomed. Anal. 9:(6):1991;435.
16. Karnes H.T., Shiu G., Shah V.P. Pharm. Res. 12:(4):1991;421.
17. CDER-FDA. Guidance for Industry. Bioanalytical Method Validation for Human Studies. Draft Guidance. December 1998.
18. Shah V.P., Midha K.K., Findlay J.A. Pharm. Res. 17:(129):2000;1551.